Search

Your search keyword '"Ixazomib"' showing total 35 results
Start Over Descriptor "Ixazomib" Publisher newsrx llc
35 results on '"Ixazomib"'

1. New Myeloma Study Findings Have Been Reported by Researchers at Tel Aviv Sourasky Medical Center (Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study)

Subjects
Bortezomib -- Standards, Ixazomib, Physical fitness, Medical centers, Health
Abstract

2020 JUL 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Myeloma have been published. According to [...]

Published
2020

3. Patent Issued for Soluble C5aR Antagonists (USPTO 10,487,098)

Subjects
Ixazomib, Angiotensin II -- Intellectual property, Palifermin -- Intellectual property, Monoclonal antibodies, Tofacitinib, Immunosuppressive agents, Fluocinolone, Halcinonide -- Intellectual property, Ciclesonide, Tixocortol, Olmesartan medoxomil -- Intellectual property, Physical fitness, Tocilizumab, Clobetasone -- Intellectual property, Nilotinib, Obinutuzumab, Antineoplastic agents -- Intellectual property, Canakinumab, Anopheles, Fingolimod, Belimumab, Basiliximab, Obesity, Alefacept, Everolimus, Ibrutinib, Ocrelizumab, Editors, Cannabidiol, Brentuximab vedotin, Pomalidomide, Belatacept, Panobinostat, Health
Abstract

2019 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A patent by the inventors Fan, Pingchen (Fremont, CA); Krasinski, Antoni (Sunnyvale, [...]

Published
2019

4. Researchers Submit Patent Application, 'SOLUBLE C5aR ANTAGONISTS', for Approval (USPTO 20190270761)

Subjects
Ixazomib, Angiotensin II -- Intellectual property, Palifermin -- Intellectual property, Monoclonal antibodies, Tofacitinib, Immunosuppressive agents, Fluocinolone, Halcinonide -- Intellectual property, Ciclesonide, Tixocortol, Olmesartan medoxomil -- Intellectual property, Physical fitness, Tocilizumab, Clobetasone -- Intellectual property, Nilotinib, Obinutuzumab, Antineoplastic agents -- Intellectual property, Canakinumab, Anopheles, Fingolimod, Belimumab, Basiliximab, Obesity, Alefacept, Everolimus, Ibrutinib, Ocrelizumab, Editors, Cannabidiol, Brentuximab vedotin, Pomalidomide, Belatacept, Panobinostat, Health
Abstract

2019 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Washington, D.C., NewsRx journalists report that a patent application by the [...]

Published
2019

5. Investigators at Mayo Clinic Zero in on Multiple Myeloma (Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance)

Subjects
Ixazomib, Physical fitness, Lenalidomide, Dexamethasone, Obesity, Glucocorticoids, Editors, Health
Abstract

2019 JUL 20 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Oncology - Multiple Myeloma have been presented. According to [...]

Published
2019

6. Takeda's Ninlaro Drug Overview 2019 with Sales by Country 2017-2026 - ResearchAndMarkets.com

Subjects
Johnson & Johnson, Ixazomib, Physical fitness, Multiple myeloma, Pharmaceutical industry, Obesity, Proteins, Apoptosis, Tumors, Editors, Bortezomib, Health, Ninlaro (Medication)
Abstract

2019 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- The 'Ninlaro' report has been added to ResearchAndMarkets.com's offering. Ninlaro (ixazomib; Takeda) [...]

Published
2019

7. Patent Issued for Soluble C5aR Antagonists (USPTO 10,329,314)

Subjects
Tromethamine -- Intellectual property, Ixazomib, Angiotensin II -- Intellectual property, Palifermin -- Intellectual property, Monoclonal antibodies, Tofacitinib, Immunosuppressive agents, Fluocinolone, Halcinonide -- Intellectual property, Ciclesonide, Tixocortol, Olmesartan medoxomil -- Intellectual property, Physical fitness, Tocilizumab, Clobetasone -- Intellectual property, Nilotinib, Obinutuzumab, Antineoplastic agents -- Intellectual property, Canakinumab, Anopheles, Fingolimod, Belimumab, Basiliximab, Fashion designers, Obesity, Alefacept, Everolimus, Editors, Brentuximab vedotin, Pomalidomide, Belatacept, Health
Abstract

2019 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- ChemoCentryx Inc. (Mountain View, California, United States) has been issued patent number [...]

Published
2019

8. Researchers Submit Patent Application, 'Use Of Cannabinoids In The Treatment Of Multiple Myeloma', for Approval (USPTO 20190175547)

Subjects
Carfilzomib, Ixazomib, Physical fitness, B cells, Pomalidomide, Cannabinoids, Multiple myeloma, Phenols (Class of compounds) -- Intellectual property, Obesity, Cancer, Editors, Health
Abstract

2019 JUL 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Washington, D.C., NewsRx journalists report that a patent application by the [...]

Published
2019

9. New Findings in Multiple Myeloma Described from University Hospital Wurzburg (Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma)

Subjects
Carfilzomib, Ixazomib, Physical fitness, Panobinostat, Multiple myeloma, Obesity, Editors, Bortezomib, Health
Abstract

2019 MAY 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Oncology - Multiple Myeloma. According to news [...]

Published
2019

10. New Findings from J. Brus et al Broadens Understanding of Proteasome Inhibitors (Determining the Crystal Structures of Peptide Analogs of Boronic Acid In the Absence of Single Crystals: Intricate Motifs of Ixazomib Citrate Revealed By Xrpd ...)

Subjects
Peptides, Crystal structure, Physical fitness, Ixazomib, Obesity, Cancer treatment, Editors, Health
Abstract

2019 MAY 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Drugs and Therapies - Proteasome Inhibitors. According [...]

Published
2019

11. 'Combination Treatment For Cancer' in Patent Application Approval Process (USPTO 20200270354)

Subjects
Carfilzomib, Ixazomib, Intellectual property, Cancer, Amino acids -- Intellectual property, Intellectual property, Business, Health, Health care industry
Abstract

2020 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- A patent application by the inventors KHANDEKAR, Sanjay (Collegeville, PA); MAYES, Patrick (Devon, PA); OPALINSKA, [...]

Published
2020

13. Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO[TM] ixazomib in Multiple Myeloma as a First-Line Maintenance Therapy

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Clinical trials, Ixazomib, Multiple myeloma, Stem cells, Pharmaceutical industry -- Product development, Stem cell transplantation, Health, Ninlaro (Medication) -- Product development
Abstract

2020 JUN 29 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ('Takeda') announced it will orally present the results of two [...]

Published
2020

14. Researchers Submit Patent Application, 'Combination Of Small Molecule CD-47 Inhibitors With Other Anti-Cancer Agents', for Approval (USPTO 20200147054)

Subjects
Cabazitaxel, Ixazomib, Ceritinib, Zoledronate, Ruxolitinib -- Intellectual property, Ramucirumab, Olaparib, Nivolumab, Carboplatin -- Intellectual property, Obinutuzumab, Nandrolone -- Intellectual property, Rasburicase -- Intellectual property, Pamidronate -- Intellectual property, Cancer, Monoclonal antibodies, Alitretinoin -- Intellectual property, Pembrolizumab, Pegfilgrastim, Belinostat, Decitabine, Durvalumab -- Intellectual property, Palbociclib, Idelalisib, Blinatumomab, Bevacizumab -- Intellectual property, Nilotinib, Plerixafor, Antineoplastic agents -- Intellectual property, Afatinib, Cancer treatment, Temsirolimus, Fulvestrant, Clofarabine, Pertuzumab, Dasatinib, Nelarabine, Ixabepilone, Axitinib, Vincristine, Ibrutinib, Editors, Tositumomab, Abiraterone, Dabrafenib, Pemetrexed, Cetuximab, Pomalidomide, Carfilzomib, Romidepsin, Atezolizumab, Ipilimumab, Technology, Pralatrexate, Enzalutamide, Sunitinib, Niraparib, Regorafenib, Crizotinib, Necitumumab, Baricitinib, Lapatinib, Interferon alfa-2a, Degarelix, Biotechnology, Talazoparib, Dinutuximab, Everolimus, Vorinostat, Ponatinib, Bosutinib, Rucaparib, Panitumumab, Ofatumumab, Sorafenib, Bendamustine, Ibritumomab tiuxetan, Trametinib, Denosumab, Vemurafenib, Pazopanib, Eculizumab, Aflibercept, Panobinostat, Daratumumab, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2020 JUN 3 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors Ramachandra, Muralidhara [...]

Published
2020

15. New Multiple Myeloma Study Findings Recently Were Reported by Researchers at Belarusian State Medical University (Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: Results of a prospective clinical study)

Subjects
Clinical trials, Ixazomib, Multiple myeloma -- Drug therapy, Vaccination, Mortality, Pneumonia, Infection, Editors, Diseases, Health
Abstract

2020 JUN 3 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Research findings on Oncology - Multiple Myeloma are discussed in a new report. According to [...]

Published
2020

16. Reports from Millennium Pharmaceuticals Advance Knowledge in Myeloma (Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-kB pathway activation)

Subjects
Millennium Pharmaceuticals Inc., Ixazomib, Biotechnology industries -- Genetic aspects, Multiple myeloma -- Genetic aspects -- Drug therapy, Gene expression -- Genetic aspects, Lenalidomide, Dexamethasone, Biochemistry, Genes, Anopheles, Glucocorticoids, Tumors, Lithium compounds, Editors, Health
Abstract

2020 MAY 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators discuss new findings in Oncology - Myeloma. According to news reporting originating from Cambridge, [...]

Published
2020

17. AI finds 9 potential COVID-19 drugs that can be used on humans immediately

Subjects
Ixazomib, Coronaviruses, Afatinib, Nitazoxanide, Drug approval, Drug discovery, Business, Health, Health care industry
Abstract

2020 APR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Gero used its AI drug discovery platform to identify molecules [...]

Published
2020

18. Researchers Submit Patent Application, 'Par-4 Agonists For The Treatment Of Cancer', for Approval (USPTO 20200046721)

Subjects
Cipla Ltd. -- Intellectual property, Cabazitaxel, Ixazomib, Ceritinib, Ionizing radiation, Cobimetinib, Ruxolitinib, Siltuximab, Alectinib, BCR-ABL tyrosine kinase inhibitors, Ramucirumab, Trifluridine, Olaparib, Nivolumab, Carboplatin, Obinutuzumab, Antibacterial agents, Cancer genetics -- Genetic aspects, Osimertinib, Cancer -- Genetic aspects, Monoclonal antibodies, Pembrolizumab, Belinostat, Decitabine, Palbociclib, Idelalisib, Blinatumomab, Bevacizumab, Pharmaceutical industry -- Intellectual property, Antineoplastic agents, Afatinib, Cancer treatment, Anopheles, Temsirolimus, Cabozantinib, Fulvestrant, Clofarabine, Pertuzumab, Dasatinib, Nelarabine, Ixabepilone, Axitinib, Vincristine, Ibrutinib, Editors, Sonidegib, Lenvatinib, Nilotinib, Tositumomab, Abiraterone, Dabrafenib, Pemetrexed, Vandetanib, Cetuximab, Carfilzomib, Romidepsin, Atezolizumab, Ipilimumab, Vismodegib, Trabectedin, Elotuzumab, Pralatrexate, Enzalutamide, Sunitinib, Regorafenib, Crizotinib, Necitumumab, Lapatinib, Degarelix, Public health, Dinutuximab, Everolimus, Vorinostat, Ponatinib, Bosutinib, Public health movements, Panitumumab, Brentuximab vedotin, Ofatumumab, Sorafenib, Bendamustine, Ibritumomab tiuxetan, Trametinib, Denosumab, Vemurafenib, Pazopanib, Panobinostat, Daratumumab, Biotechnology industry, Health, Science and technology
Abstract

2020 MAR 2 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors [...]

Published
2020

19. Reports Outline Anticancer Agents Study Results from University of Auckland (Novel Cell-Penetrating Peptide Conjugated Proteasome Inhibitors: Anticancer and Antifungal Investigations)

Subjects
Ixazomib, Antifungal agents, Antiparasitic agents, Fungi, Amphotericin B, Editors, Company legal issue, Health, University of Auckland -- Investigations
Abstract

2020 JAN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in Drugs and Therapies - Anticancer Agents. According to [...]

Published
2020

20. Recent Studies from Keio University Add New Data to Multiple Myeloma (Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets)

Subjects
Ixazomib, Elotuzumab, Biopharmaceuticals, Multiple myeloma, Immunotherapy, Daratumumab, Antineoplastic agents, Monoclonal antibodies, Operating systems (Software), Pomalidomide, Carfilzomib, Antibodies, Lenalidomide, Panobinostat, Editors, Bortezomib, Novels, Health, Keio University
Abstract

2019 DEC 11 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators discuss new findings in Oncology - Multiple Myeloma. According to news reporting from Tokyo, [...]

Published
2019

21. Patent Application Titled 'Uses Of Bcl-2 Antagonists For Treating Cancer And Diagnostics Related Thereto' Published Online (USPTO 20190328729)

Subjects
Cabazitaxel, Ixazomib, Ceritinib, Cobimetinib, Ruxolitinib -- Intellectual property, Acalabrutinib -- Intellectual property, Romiplostim -- Intellectual property, Siltuximab, Glucarpidase, Alectinib, Aminolevulinic acid -- Intellectual property, Midostaurin -- Intellectual property, BCR-ABL tyrosine kinase inhibitors, Ramucirumab, Trifluridine -- Intellectual property, Olaparib, Nivolumab, Carboplatin -- Intellectual property, Obinutuzumab, Lanreotide, Methylnaltrexone, Brigatinib -- Intellectual property, Rasburicase -- Intellectual property, Pamidronate -- Intellectual property, Axicabtagene ciloleucel -- Intellectual property, Enasidenib -- Intellectual property, Osimertinib, Palifermin -- Intellectual property, Cancer, Monoclonal antibodies, Pembrolizumab, Inotuzumab ozogamicin -- Intellectual property, Belinostat, Neratinib -- Intellectual property, Zoledronic acid, Decitabine, Copanlisib -- Intellectual property, Durvalumab -- Intellectual property, Palbociclib, Idelalisib, Blinatumomab, Bevacizumab -- Intellectual property, Antiemetics -- Intellectual property, Plerixafor, Abemaciclib -- Intellectual property, Eltrombopag -- Intellectual property, Talimogene laherparepvec, Antineoplastic agents -- Intellectual property, Afatinib, Temsirolimus, Cabozantinib, Fulvestrant, Pertuzumab, Dasatinib, Nelarabine, Axitinib, Ibrutinib, Sonidegib, Nilotinib, Abiraterone, Dabrafenib, Pemetrexed, Pomalidomide, Carfilzomib, Olaratumab, Enzalutamide, Sunitinib, Niraparib, Crizotinib, Necitumumab, Lapatinib, Dinutuximab, Ponatinib, Bosutinib, Rucaparib, Ofatumumab, Sorafenib, Bendamustine, Trametinib, Vemurafenib, Tumors, Ribociclib, Aflibercept, Panobinostat, Cancer treatment, Anopheles, Clofarabine, Ixabepilone, Vincristine, Editors, Lenvatinib, Rolapitant, Vandetanib, Aprepitant, Cetuximab, Atezolizumab, Romidepsin, Ipilimumab, Venetoclax, Trabectedin, Vismodegib, Elotuzumab, Pralatrexate, Regorafenib, Degarelix, Everolimus, Vorinostat, Avelumab, Palonosetron, Panitumumab, Brentuximab vedotin, Ibritumomab tiuxetan, Denosumab, Pazopanib, Daratumumab, Business, Health, Health care industry
Abstract

2019 NOV 19 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by [...]

Published
2019

23. Wilhelminen Cancer Research Institute Details Findings in Multiple Myeloma (Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma)

Subjects
Ixazomib, Cancer, Cancer research, Multiple myeloma, Thalidomide, Dexamethasone, Glucocorticoids, Editors, Central nervous system depressants, Health
Abstract

2019 OCT 18 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Oncology - Multiple Myeloma is the subject of a report. [...]

Published
2019

24. Researchers at European Medicines Agency Report New Data on Multiple Myeloma [European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy]

Subjects
Ixazomib, Dexamethasone, Marketing, Lenalidomide, Glucocorticoids, Editors, Health
Abstract

2019 OCT 11 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on Oncology - Multiple Myeloma is now available. According to [...]

Published
2019

25. Reports Outline Medical Technology Findings from University of Lyon (Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma)

Subjects
Ixazomib, Drugs, Recurrence (Disease), Multiple myeloma, Medical technology, Technology, Editors, Health
Abstract

2019 SEP 27 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Technology - Medical Technology. According to news reporting [...]

Published
2019

26. 'Enhancement Of Cd47 Blockade Therapy By Proteasome Inhibitors' in Patent Application Approval Process (USPTO 20190255082)

Subjects
Trillium Therapeutics Inc. -- Intellectual property, Carfilzomib, Ixazomib, Pharmaceutical industry -- Intellectual property, Cancer cells, Cancer, Editors, Health
Abstract

2019 SEP 9 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- A patent application by the inventors Linderoth, Emma (Toronto, ON, CA); Viller, Natasja Nielsen [...]

Published
2019

27. Research Conducted at Division of Hematology Has Updated Our Knowledge about Multiple Myeloma (Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma)

Subjects
Ixazomib, Multiple myeloma, Bendamustine, Dexamethasone, Recurrence (Disease), Toxicity, Lenalidomide, Antineoplastic agents, Glucocorticoids, Editors, Bortezomib, Health
Abstract

2019 AUG 16 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Oncology - Multiple Myeloma. According to news reporting [...]

Published
2019

28. Patent Issued for Combinations Of Proteasome Inhibitors And Cyclic Peptides (USPTO 10,328,116)

Subjects
Ixazomib, Bevacizumab -- Intellectual property, Peptides, Amino acids -- Intellectual property, Antineoplastic agents -- Intellectual property, Biotechnology, Cetuximab, Editors, Carfilzomib, Sunitinib, Bortezomib, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2019 JUL 10 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- Big Dna Ltd. (Roslin, Midlothian, United Kingdom) has been issued patent number 10,328,116, according to [...]

Published
2019

29. 'Combination Therapy' in Patent Application Approval Process (USPTO 20190175687)

Subjects
Ixazomib, Bevacizumab -- Intellectual property, Amino acids -- Intellectual property, Antineoplastic agents -- Intellectual property, DNA, Biotechnology, Cetuximab, Editors, Carfilzomib, Sunitinib, Bortezomib, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2019 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- A patent application by the inventors March, John BERNARD (Roslin, GB); Clark, Ewan McIntosh (Roslin, [...]

Published
2019

30. 'Combination Therapy' in Patent Application Approval Process (USPTO 20190134148)

Subjects
Ixazomib, Bevacizumab -- Intellectual property, Amino acids -- Intellectual property, Antineoplastic agents -- Intellectual property, Cetuximab, Editors, Carfilzomib, Sunitinib, Bortezomib, Health
Abstract

2019 MAY 27 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- A patent application by the inventors MARCH, John Bernard (Roslin, Midlothian, GB); CLARK, Ewan McIntosh [...]

Published
2019

32. Studies from University College Provide New Data on Biomarkers (Non-invasive Imaging of Disrupted Protein Homeostasis Induced By Proteasome Inhibitor Treatment Using Chemical Exchange Saturation Transfer Mri)

Subjects
Journalistic ethics, Biological markers, Ixazomib, Homeostasis, Editors, Health
Abstract

2019 MAY 3 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on Diagnostics and Screening - Biomarkers have been presented. According to [...]

Published
2019

33. Patent Issued for Mesalamine For The Treatment Of Cancer (USPTO 10,220,072)

Subjects
Cipla Ltd. -- Intellectual property, Pharmaceutical industry -- Intellectual property, Ruxolitinib, Alectinib, Ixazomib, Nivolumab, Cobimetinib, Pembrolizumab, Idelalisib, Cancer, Osimertinib, Ramucirumab, Obinutuzumab, Antifungal agents, Ionizing radiation, Decitabine, Immunotherapy, Mesalamine, Ceritinib, Blinatumomab, Bevacizumab, Patient compliance, Monoclonal antibodies, BCR-ABL tyrosine kinase inhibitors, Antineoplastic agents, Cancer treatment, Denosumab, Pazopanib, Ipilimumab, Nilotinib, Kidney cancer, Bosutinib, Ofatumumab, Vandetanib, Temsirolimus, Lapatinib, Tositumomab, Axitinib, Sunitinib, Panitumumab, Ponatinib, Dasatinib, Cetuximab, Cabozantinib, Pertuzumab, Crizotinib, Everolimus, Carcinoma, Ibritumomab tiuxetan, Editors, Sorafenib, Renal cell carcinoma, Nelarabine, Anopheles, Health
Abstract

2019 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- A patent by the inventors Malhotra, Geena (Mumbai, IN); Joshi, Kalpana (Maharashtra, IN); Ghosalkar, Jeevan [...]

Published
2019

34. Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma

Subjects
Carfilzomib, Clinical trials, Daratumumab, Ixazomib, Multiple myeloma -- Care and treatment, Dexamethasone -- Product development, Immunotherapy, Pomalidomide, Recurrence (Disease) -- Care and treatment, Chemotherapy, Cancer treatment, Cancer, Immune system, Editors, Glucocorticoids, Cancer cells, Steroids (Organic compounds), Health
Abstract

2019 MAR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Staff editors report on the newly launched clinical trial, NCT03841565, which has the following summary [...]

Published
2019

35. Studies from National and Kapodistrian University of Athens in the Area of Multiple Myeloma Reported (Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma)

Subjects
Multiple myeloma -- Drug therapy, Carfilzomib, Ixazomib, Chemotherapy, Bortezomib, Clinical trials, Editors, Drugs, Lenalidomide, Health
Abstract

2019 FEB 11 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Current study results on Oncology - Multiple Myeloma have been published. According to news reporting [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results